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Objectives: Peroxynitrite is species claimed to pro-
pagate ischemia/reperfusion damage. In this re-
port levels of serum uric acid (UA), a peroxynitri-
te scavenger, are compared with creatine phosph-
okinase (CPK) in male patients before and after
open-heart surgery in order to asses if increased
levels of UA may protect heart from biochemical
damage induced by peroxynitrite during the coronary
by-pass grafting (CABG) intervention. 
Methods: 45 male patients (16 carvedilol pretreated
(6.25 mg/ daily, during 6 weeks before surgery, mean
age 55.3+1.7 years, range 50-71) and 29 patients with-
out carvedilol pretreatment (mean age 58.3+1.4 years,
range 47-73) underwent elective CABG were exam-
ined. Study inclusion criteria were CABG performed
on two and more coronary–vessels with aortic cross-
clamp during 30-40 minutes. For assessment of pa-
tients objective health status before operations Euro-
SCORE were used. Serum uric acid (UA) levels and
creatine phosphokinase (CPK) were measured spec-
trophotometricaly by using a quantitative enzymatic
assay. 
Results: Carvedilol pretreated patients had higher
amount of serum UA (p<0.05) comparing to non-tre-
ated patients. During the surgical procedure patients
are subjected to temporary ischemia due to transfer
from corporeal to extracorporeal circulation. In this
period of time the amount of UA decreased in carve-
dilol pretreated group (406+46 (t1) vs. 300+22 mmol/L
(t2)) to the level of non-treated patients (328+14 (t1)
vs. 322+18 mmol/L. Carvedilol pretreated patients and
non-treated patients had the same level of CPK at the
beginning of the surgical procedure (t1) (78+6 vs.
83+13 U/L) but lower increase (p<0.05) in CPK activi-
ty in carvedilol pretreated patients in respect to non-
treated patients (338+46 vs. 644+103 U/L) at the end of
procedure (t2). Such results suggest that open heart
surgery led to elevated CPK levels, but this effect was
less pronounced in patients with higher level of UA. 
Conclusions: Our results suggest possible role of UA in
the protection from reperfusion injury. Increase of UA
before surgery may be beneficial factor during CABG
procedure in patients treated with carvedilol by de-
creasing level of peroxynitrite as one of molecular cau-
ses of reperfusion injury. Our results showed influence
of UA on CPK levels at the end of surgical procedure,
indicating that increased levels of UA may protect he-
art from biochemical damage induced by peroxynitrite
during the CABG intervention.
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INTRODUCTION 
It is well known that in patients undergoing the open-heart surgery, in the coronary by-pass grafting (CABG)
intervention, oxidative stress occurred1-3. Myocardial and
endothelial damages are still widely debated problem dur-
ing ischemia-reperfusion sequence in heart surgery. The
critical problem associated with this procedure is linked
with the series of events such as block of oxidative phos-
phorilation and the increase in nitric oxide (NO) and oxy-
gen free radical production. In addition, significant comp-
lication arising from CABG is ischemia/reperfusion injury
(I/R) and subsequent large number of free radicals are re-
leased, due to, among others, metabolism of xanthine oxi-
dase, activation of neutrophils and catecholamine oxidati-
on3. Data also indicates that oxidative stress and endothe-
lial damage are major events during CABG, thus over-
whelming the scavenging capacity of myocyte and preve-
nting restoration of normal energy balance for 30 min. af-
ter reperfusion. All these alterations have been extensively
characterized under experimental conditions4, as well as
peroxynitrite role in local and multisystem injury5  but
there were a scarce data on their relationship at clinical
level.
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Among the many well-known antioxidants, the role of
uric acid (UA) in the antioxidant system was not establi-
shed. Uric acid has been used in clinical practice as a mar-
ker of several metabolic disturbances, although until re-
cently its antioxidant properties in vivo had not been con-
sidered. UA has much higher antioxidant capacity then
other low molecular antioxidants6. Among the many bene-
ficial characteristics, probably the most interesting is the
capability of UA to scavenge peroxynitrite (ONOO-) di-
rectly7. On the other hand, it is well known that ONOO-
has been implicated in the etiology of reperfusion injury
and other cardiovascular disease8,9. Teng et al10 suggested
that although xanthine dehydrogenase (XDH) conversion
to a free radical-producing oxidase can serve as an impor-
tant source of superoxide and hydrogen peroxide during
I/R sequence, urate formation by XDH may provide a sig-
nificant antioxidant defense against peroxynitrite and re-
lated NO-derived oxidants. Skinner et al.11 showed the ca-
pability of UA not only to scavenge ONOO- but also to
produce a vasoactive nitric oxide (.NO) donor. Release of
.NO from nitrosated UA derivative following insults such
as ischemia/reperfusion could minimize tissue injury and
thereby constitute a previously uncharacterized role for
UA in human physiology.
In this paper we examined how increased level in serum
UA in patients pretreated with carvedilol undergoing
open-heart surgery influences CPK levels, as the marker
of tissue damage degree – both mechanical and biochemi-
cal,  in CABG intervention. 
MATERIALS AND METHODOLOGY
We studied 45 male patients (16 carvedilol pretreated
patients, mean age 55.3+1.7 years, range 50-71, and 29
controls, mean age 58.3+1.4 years, range 47-73) underwe-
nt elective coronary artery bypass grafting (CABG). Stu-
dy inclusion criteria were CABG performed on two and
more coronary–vessels with aortic cross-clamp during 30-
40 minutes. For assessment of patients objective health
status before operations we used EuroSCORE (European
system for cardiac operative risk evaluation). Euro-
SCORE is a simple, objective and up-to-date system for
assessing heart surgery, soundly based on one of the larg-
est, most complete and accurate databases in European
cardiac surgical history12. The clinical characteristics of
elected patients are shown in Table 1. There was no ope-
rative mortality in this study. Written consent was obta-
ined from each patient after formal information regarding
participation in this study.
Patients were divided in two groups: 1) patients re-
ceived preoperatively carvedilol (6.25 mg once per day)
during six weeks before operation (16 patients) and 2) pa-
tients prepared for CABG without carvedilol therapy (29
patients). Vein blood was taken at two time points: (t1)
before cross-clamp (2 min. after heparin application) and
(t2) 30 min. after declamp (30 min. after reperfusion, e.g.
15-20 min. after heparin neutralization with protamine
sulphate). 
Serum uric acid (UA) levels and creatine phosphokinase
(CPK) were measured on Shimadzu UV 260 spectro-
photometer by using a quantitative enzymatic assay (Bio-
Systems-Spain) according to the manufacturer’s protocol.
Results for UA were standardized by using standard solu-
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FIGURE 1
LEVELS OF URIC ACID (UDA) MEASURED BEFORE (T1)
AND AFTER CROSS/CLAMP(T2). T1-2 MIN AFTER HEPA-
RIN APPLICATION AND T2-30 MIN AFTER DECLAMP
(30 MIN AFTER PERFUSSION, EG 15-20 MIN AFTER
HEPARIN NEUTRALIZATION WITH PROTAMINE SUL-
PHATE) RESULTS ARE EXPRESSED AS MEAN S.E.M.
(N=16 FOR CARVEDILOL PRETREATED PATIENTS,
N=29 FOR NON-TREATED PATIENTS)
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FIGURE 2
ACTIVITY OF CREATIN PHOSPHOKINASE (CPK) MEAS-
URED BEFORE (T1) AND AFTER CROSS-CLAMP (T2). T1-
2 MIN AFTER HEPARIN APPLICATION AND 72-30 MIN
AFTER DECLAMP (30 MIN AFTER REPERFUSION, E.G.
15-20 MIN AFTER HEPARIN NEUTRALIZATION WITH
PROTAMINE SULPHATE). RESULTS ARE EXPRESSED
AS MEAN S.E.M (N=16 FOR CARVEDILOL PRETREATED
PATIENTS, N=29 FOR NON-TREATED PATIENTS) 
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tions of UA provided by manufacturer (BioSystems-
Spain). 
Data are presented as mean  SEM. Comparisons bet-
ween groups of patients were performed by Two-way
ANOVA (treatment and time as effect) followed by
Scheffe t-test. Values of P were considered significant.
RESULTS  
In this study we demonstrated that elevated serum UA
(in carvedilol pretreated patients) before the open-heart
surgery had certain benefit effects for patients underwent
open-heart surgery. Carvedilol pretreated patients had
higher amount of serum UA (p<0.05) comparing to non-
treated patients (Fig.1). During the surgical procedure pa-
tients are subjected to temporary ischemia due to transfer
from corporeal to extracorporeal circulation. In this period
of time the amount of UA decreased in carvedilol pre-
treated gro-up (406+46 (t1) vs. 300+22 mmol/L (t2)) to
the level of non-treated patients (328+14 (t1) vs. 322+18
mmol/L (t2), significant difference between carvedilol
pretreated patients and non treated and difference in time
effect and interactions, Two way ANOVA, Scheffe t-test
p<0.05, Table 2.). 
Carvedilol pretreated patients and non-treated patients
had the same level of CPK at the beginning of the surgical
procedure (t1) (78+6  vs. 83+13 U/L) but lower increase
(p>0.05) in CPK activity in carvedilol pretreated patients
in respect to non-treated patients (338+46 vs. 644+103
U/L) at the end of procedure (t2) (Fig.2, Table 2).
Such results suggest that open heart surgery led to ele-
vated CPK levels, but this effect was less pronounced in
patients with higher level of UA (significant time and
treatment effect as well as their interactions, Two way
ANOVA, Scheffe t-test p<0.05, Table 2.).
Table 2. Two-way analysis of variance (ANOVA) fol-
lowed with Scheffe t-test of investigated groups. Effects:
treatment (Tr), time (T) and interactions (Tr x T). Df – de-
gree of freedom, MS – mean square and F- F value. 
DISCUSSION:
Although urate was denoted as possible cardiovascular
risk factor13 and its scavenger activity was reassessed by
other researchers14 there are data that show its beneficial
role in human physiology and pathophysiology. Best ex-
amples are application of urate in healthy volunteers15
which showed greater capacity of UA in scavenging free
radicals than vitamin C. This work also suggested, in view
of UA antioxidant properties, that UA might have poten-
tially important and beneficial effects within cardiovascu-
lar system. Other authors showed beneficial role of UA in
treatment of experimental allergic encephalomyelitis16,17
and multiple sclerosis17,18.
Up to date it is well documented that cardiac surgery,
especially cardiopulmonary bypass followed with extraco-
rporeal circulation is accompanied with extensive oxidati-
ve stress1-3,19 that aggravate postoperative prognosis for
patients. In order to prevent oxidative stress in such pati-
ents different approaches were used. This includes appli-
cation of free radical scavengers such as vitamin C, vita-
min E, glutathione or different enzyme mimetic, or vari-
TABLE 1
CLINICAL CHARACTERIZATION OF PATIENTS
Characteristics Control group (n=29) Carvedilol group (n=16)
Mean age(years) 58.2+11.4 (47-73) 55.3+11.7 (50-71)
EuroSCORE 2.92 4.67
EF before /EF after CABG 42.41/42.22 32.14/31.07
Number of grafts per patients 2.8+0.1 2.9+0.2
TABLE  2
TWO-WAY ANALYSIS OF VARIANCE (ANOVA) FOLLOWED WITH SCHEFFE t-TEST OF INVESTIGATED
GROUPS
Treatment (Tr) Time (T) TrxT Error
UA
df 1 1 1 85
MS 189002 53731 44002 10059
F 1.88 5.34* 4.37*
CPK
dr 1 1 1 71
MS 406327 2849312 382069 84085
F 4.83* 33.89*** 4.54*
Effects:treatment (Tr), time (T) and interactions (Tr x T). Df - degree of freedom, MS - mean square and F - F value 
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ous enzyme inhibitors, but neither approach resolved the
problem. Recently UA has attracted attention by its ability
to scavenge peroxynitrite in direct reaction7. 
Comparison of two groups of patients, carvedilol treated
and non-treated showed that treated patients have higher
level of UA (Fig.1, p<0.05). This results further show that
hi-gher endogenous urate was far more protective since
tissue damage was less pronounced in carvedilol treated
group (with higher level of UA) expressed through CPK
activity (p<0.05). CPK is known to be a marker for heart
tissue damage widely used in cardiology. Our results
showed that although both group of patients were sub-
jected to mechanical damage during surgery, biochemical
damage (e.g. protein nitration due to peroxynitrite forma-
tion during ischemia, as well as subcellular damage due to
free radical generation) was statistically lower in the
group of patients with higher UA level, suggesting protec-
tive role of UA. Similar effects was observed by Teng et
al.7 who showed that urate produced during hypoxia pro-
tected heart proteins from peroxynitrite-mediated protein
nitration and thus inactivation.  
Skinner et al.11 showed that UA was considerably more
susceptible to oxidation by ONOO- than other purines
(hypoxanthine and xanthine). These authors also showed
that some of the reaction products might have beneficial
effects for patients. The product of the UA/ONOO- reac-
tion resulted in endothelium-independent vasorelaxation
of rat thoracic aorta, with an EC50 value in the range of
0.03–0.3 mM. The UA nitration/nitrosation product may
play a pivotal role in human pathophysiology by releasing
.NO, which could decrease vascular tone, increase tissue
blood flow, and thereby constitute a role for UA not pre-
viously described. The importance of nitrated UA product
in such patients as well as other patients suffered from is-
chemia/reperfusion injury, acute myocardial infarction
and other CVD is greater if we consider the fact that
nominal potency of UA nitrated product is greater than
.NO donors used clinically, including glycerol trinitrate or
amyl nitrite20.
Question of UA threshold concentration for reaction
with peroxynitrite in vivo as our results show, may have
answer in postulated reaction mechanism for UA – per-
oxynitrite reaction in vitro11 and alternative mechanism in
vitro including UA reaction with NO previously  trans-
formed in to its redox congeniers - nitroxyl and nitro-
sonium ion21. 
Contrary to present state of knowledge, increase of UA
before surgery may be beneficial factor during CABG
procedure in patients treated with carvedilol by decreasing
level of peroxynitrite as one of molecular causes of reper-
fusion injury. Our results showed influence of UA on
CPK levels at the end of surgical procedure, indicating
that increased levels of UA may protect heart from bio-
chemical damage induced by peroxynitrite during the
CABG intervention. Even more, formation of nitrosative
UA derivative by peroxynitrite may result in a formation
of an vasoactive nitric oxide donor11 which may be benefi-
cial in postoperative course of recovery in these patients. 
REZIME
Ciljevi: Postoji mi{ljenje da Peroxynitrite {iri – poja~a-
va o{te}enja koja poti~u od ishemije /reperfuzije. U ovom
radu poredjen je nivo mokra}ne kiseline (UA) u serumu,
sakuplja~a peroksinitrita, sa nivoom kreatin fosfokinaze
(CPK) kod mu{karaca pre i nakon operacije na otvo-re-
nom srcu, a u cilju procene da li pove}ani nivoi UA mo-
gu slu‘iti kao za{tita od biohemijskih o{te}enja izazvanih
upotrebom peroksinitrita tokom hirur{ke CABG interven-
cije. Metode: Ispitivano je 45 bolesnika (16 je prethodno
primalo karvedilol – 6.25 mg dnevno, tokom 6 nedelja pre
operacije, prose~ne starosti 55.3+1.7 godina, 55-71, i 29
bolesnika koji nisu primali karvedilol, prose~ne starosti
58.3+1.4 godina, 47-73) koji su bili podvrgnuti CABG
hirur{koj intervenciji. Kriterijumi za uklju~enje u studiju
su bili izvodjenje CABG na dva ili vi{e sudova sa klemo-
vanjem aorte u trajanju od 30 – 40 minuta. Za procenu
zdravstvenog stanja bolesnika pre operacije kori{}en je
EuroSCORE. Nivoi UA i kreatin fosfokinaze (CPK) u se-
rumu su mereni uz pomo} spektrofotometrije kori{}enjem
kvantitativnog enzimskog eseja. Rezultati: U bolesnika
koji su prethodno primali karvedilol uo~eni su uve}ani
nivoi UA u serumu (p< 0.05) u poredjenju sa bolesnicima
koji nisu primali pomenuti lek. Tokom hirur{ke procedure
bolesnici su podvrgnuti privremenoj ishemiji zbog pre-
bacivanja sa telesnog na vantelesni krvotok. U tom perio-
du vrednosti UA su sni‘ene u bolesnika koji su prethodno
primali karvedilol (406+46 (t1) naspram 300+22 mol/L
(t2))  bolesnika koji ga nisu primali (328+14 (t1) naspram
322+18 mol/L). Bolesnici koji su primali karvedilol i oni
koji nisu imali su isti nivo CPK na po~etku hirur{ke pro-
cedure (t1) (78+6 naspram 83+13 U/L) ali je na kraju pro-
cedure uo~en ni‘i porast aktivnosti CPK (p<0.05) u boles-
nika koji su primali karvedilol u poredjenju sa bolesnici-
ma koji nisu (338+46 prema 644+103 U/L) (t2). Ovakvi
rezultati sugeri{u da intervencija na otvorenom srcu dovo-
di do pove}anja nivoa CPK, ali je taj efekat bio manje
izra‘en u bolesnika koji su imali vi{i nivo UA. Zaklju~ak:
Na{i rezultati ukazuju na mogu}u pozitivnu ulogu mok-
ra}ne kiseline u za{titi od o{te}enja koja mo‘e prouzroko-
vati reperfuzija. Pove}anje nivoa UA pre operacije mo‘e
predstavljati koristan faktor tokom CABG procedure u
bolesnika koji su primali karvedilol, jer sni‘ava nivo pero-
ksinitrita kao jedan od uzroka o{te}enja od reperfuzije.
Na{i rezultati pokazuju uticaj UA na nivoe CPK pri kraju
hirur{ke intervencije, {to pak ukazuje na to da uve}ani
nivoi UA mogu {tititi srce od biohemijskih o{te}enja
izazvana peroksinitritom tokom CABG intervencije.
Klju~e re~i: antioksidanti, oboljenja kardiovaskularnog
sistema, kreatin fosfokinaza, oksidativni
stres, mokra}na kiselina
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